Investor Relations

Investor Home

Corporate Profile

MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate... More

Stock Quote

MNOV (Common)
ExchangeNASDAQ (US Dollar)
Price$3.57
Change (%) Stock is Down 0.04 (1.11%)
Volume35,991
Data as of 10/31/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

2012 Annual Report

Recent News

More
DateTitle 
10/23/14U.S. Centers for Disease Control and Prevention (CDC) Supports Recruitment for MediciNova's Clinical Trial of MN-166 (Ibudilast) in ALSPrinter Friendly Version
10/22/14MediciNova Announces FDA Granted Orphan Drug Designation to MN-001 (tipelukast) for Idiopathic Pulmonary Fibrosis (IPF)Printer Friendly Version
10/08/14MediciNova Receives Feedback From FDA Regarding Study Protocol for Phase 2 Trial of MN-001 (tipelukast) in NASHPrinter Friendly Version
10/06/14MediciNova's MN-001 (tipelukast) NASH Abstract Selected for Late-Breaking Session at the 65th Annual AASLD Meeting in BostonPrinter Friendly Version

Upcoming Events

More
There are currently no events scheduled.

What's New

There are currently no items available.
Receive Email AlertsEmail Alert Icon
Sign up to receive email alerts whenever Medicinova Inc posts new information to the site. Just enter your email address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Recent News